Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse/Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Not applicableStudy completedNCT00049465
What this trial is testing

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

Who this might be right for
Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT04150692
What this trial is testing

Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine
Not applicableApproved For MarketingNCT02477891
What this trial is testing

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC
Not applicableStudy completedNCT05932290
What this trial is testing

Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 514
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Not applicableStudy completedNCT00003538
What this trial is testing

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)UnknownNCT01435720
What this trial is testing

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMantle Cell Lymphoma in Relapse+3 more
Senesco Technologies, Inc. 15
Testing effectiveness (Phase 2)Temporarily pausedNCT04505813
What this trial is testing

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Refractory Multiple Myeloma
NexImmune Inc. 9
Early research (Phase 1)Study completedNCT03288480
What this trial is testing

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Promontory Therapeutics Inc. 24
Not applicableApproved For MarketingNCT05757973
What this trial is testing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361
What this trial is testing

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more
Luminary Therapeutics 90
Testing effectiveness (Phase 2)Ended earlyNCT04649073
What this trial is testing

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Otsuka Pharmaceutical Co., Ltd. 11
Testing effectiveness (Phase 2)Looking for participantsNCT07312188
What this trial is testing

F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 90
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Early research (Phase 1)Ended earlyNCT01643603
What this trial is testing

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Who this might be right for
Non-Hodgkin's LymphomaHodgkin's LymphomaMyeloid Leukemia+3 more
Barbara Ann Karmanos Cancer Institute 5
Large-scale testing (Phase 3)Looking for participantsNCT06152575
What this trial is testing

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Who this might be right for
Multiple Myeloma
Pfizer 492
Testing effectiveness (Phase 2)Ended earlyNCT00437034
What this trial is testing

Aflibercept for Relapsed Multiple Myeloma

Who this might be right for
Stage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)UnknownNCT00008164
What this trial is testing

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Who this might be right for
Childhood Langerhans Cell HistiocytosisLeukemiaLymphoma+3 more
Herbert Irving Comprehensive Cancer Center 30
Early research (Phase 1)Study completedNCT01164709
What this trial is testing

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more
Swiss Cancer Institute 18
Next Page